Home

NICHOLAS J VALERIANI

CIK 1263149 · VP, Strategy & Growth · last filed 2026-05-08

NICHOLAS J VALERIANI is a VP, Strategy & Growth who has filed 57 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for EW, was dated May 8, 2026. Across all open-market trades the lifetime net is −$2.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $25.9M across reported positions. 40 SEC filings were submitted jointly with & JOHNSON JOHNSON.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$25.89M

Companies

5

Total Filings

57

Lifetime Open-Market Net

-$2.17M

Filer Profile

Reported Address
C/O EDWARDS LIFESCIENCES CORPORATION
ONE EDWARDS WAY
IRVINE, CA 92614
Related Filers
& JOHNSON JOHNSON — 40 joint filings, latest 2009-10-02
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
EW Director 84,423 $89.90 $7.59M -$530.4K 17 2026-05-08
SURGALIGN HOLDINGS, INC. (SRGA) Delisted Director 30,809 $0.18 $5.6K $52.2K 4 2022-08-17
RTI SURGICAL, INC. (RTIX) Delisted Director 0 — — $51.1K 7 2019-03-11
Roka BioScience, Inc. (ROKA) Delisted Director 7,143 — — $0 5 2017-06-30
JNJ VP, Strategy & Growth 66,487 $275.23 $18.30M -$1.74M 22 2009-10-02

Recent Filings

57 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-08 EW Grant (A) +5,127 $0 EDGAR
2025-05-09 EW Grant (A) +5,564 $0 EDGAR
2024-05-09 EW Grant (A) +4,818 $0 EDGAR
2023-05-15 EW Grant (A) +2,803 $0 EDGAR
2022-08-17 SURGALIGN HOLDINGS, INC. (SRGA) Delisted Grant (A) +22,857 $0 EDGAR
2022-05-05 EW Grant (A) +2,300 $0 EDGAR
2021-11-24 EW Buy (P) +1,500 $168.3K EDGAR
2021-08-13 SURGALIGN HOLDINGS, INC. (SRGA) Delisted Buy (P) +55,000 $52.2K EDGAR
2021-07-02 SURGALIGN HOLDINGS, INC. (SRGA) Delisted Grant (A) +72,254 $0 EDGAR
2021-05-10 SURGALIGN HOLDINGS, INC. (SRGA) Delisted Grant (A) +57,803 $0 EDGAR
Showing 1–10 of 57
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.